Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
[ad_1] Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement…